docetaxel (Taxotere)

Subscribe to Selected New Research on docetaxel

3278 relevant articles (543 outcomes, 1507 trials/studies) found for this Drug

Description: semisynthetic analog of taxol; structure given in first source; RN given refers to anhydrous compound; 148408-66-6 is the isomer (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))

Also Known As:

Taxotere; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; NSC 628503; RP 56976; RP-56976; Taxoltere metro; docetaxel, isomer; docetaxol; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Cyclic Hydrocarbons: 2

Alicyclic Hydrocarbons: 1

Experts

1.	Georgoulias, V: 25 articles (05/2008 - 01/2000)
2.	Beer, Tomasz M: 16 articles (02/2008 - 01/2002)
3.	Georgoulias, Vassilis: 16 articles (05/2008 - 04/2002)
4.	Noguchi, Shinzaburo: 14 articles (02/2008 - 01/2002)
5.	Kakolyris, S: 13 articles (01/2006 - 01/2000)
6.	Dreicer, Robert: 13 articles (12/2007 - 01/2003)
7.	Mavroudis, D: 13 articles (05/2008 - 01/2000)
8.	Petrylak, Daniel P: 12 articles (01/2008 - 01/2003)
9.	Gandara, David R: 12 articles (11/2007 - 04/2003)
10.	Lara, Primo N: 11 articles (11/2007 - 04/2003)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/01/2000 - "We consider intra-arterial infusion using docetaxel to be highly effective with few side effects in cases of advanced breast cancer." 07/01/2002 - "BACKGROUND: Docetaxel has proven efficacy in metastatic breast cancer" 04/01/2000 - "Docetaxel has proven effective in advanced breast cancer" 01/01/2005 - "High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer." 06/01/2002 - "The consistent demonstration of a high level of efficacy with manageable toxicity ensures the continued widespread investigation of docetaxel in metastatic breast cancer." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 03/01/2001 - "Docetaxel delayed tumor growth and enhanced the efficacy of radiation: it dramatically reduced TCD50 (radiation dose yielding 50% tumor cure) from the control value of 38.6 Gy to 11.8 Gy, for an enhancement factor of 3.27" 12/15/1997 - "In vivo, docetaxel has substantial activity against a multitude of murine and human tumor models; in some cases, there was complete remission of advanced disease" 09/01/2008 - "Combination treatment with docetaxel resulted in significantly improved reduction in tumor growth beyond that afforded by docetaxel alone (P <or= 0.03)" 07/01/2008 - "BACKGROUND: Docetaxel has benefited from focused evaluation of its preclinical pharmacology and pharmacokinetics, as well as the evolving areas that are becoming significant to cancer drug development: pharmacogenetics, population pharmacokinetics, and in vivo quantitative pharmacology" 12/01/2005 - "The goal of the present study was to define the efficacy of neoadjuvant docetaxel in treatment-naïve large, locally advanced breast cancers and to better understand docetaxel's mechanism of action by evaluating biomarker modulation in response to treatment" Get all the results and reference details, order at left...
3.	Small Cell Carcinoma (Small Cell Lung Cancer) 10/01/1999 - "Results of a multicenter phase III trial of docetaxel versus best supportive care for the first-line treatment of non-small cell lung cancer are pending" 01/01/2003 - "The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease" 10/01/2007 - "CONCLUSION: According to this meta-analysis, docetaxel is superior to vinca alkaloid-based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer." 09/01/2004 - "CONCLUSIONS: Although the validity of the results of this study is limited due to the small sample size, docetaxel appears effective in selected elderly patients with advanced non-small-cell lung cancer." 12/01/2004 - "Docetaxel is the standard of care in second-line therapy of advanced non-small-cell lung cancer (NSCLC) and is effective, alone and in combination, in first-line treatment of advanced NSCLC" Get all the results and reference details, order at left...
4.	Prostatic Neoplasms (Prostate Cancer) 11/01/2007 - "One of the major obstacles in curing prostate cancer is the development of drug resistance to docetaxel, which is the gold standard for the treatment of this disease" 09/01/2007 - "Recently, docetaxel has been added to standard androgen ablation as an effective treatment for advanced prostate cancer." 01/15/2004 - "Taxotere is a cytotoxin effective in treating breast and prostate cancer" 05/01/2006 - "Docetaxel has been shown to improve survival in patients with metastatic prostate cancer" 08/01/2008 - "The most relevant studies involving patients with prostate cancer receiving therapy with docetaxel, alone or in combination with other agents, have been summarised" Get all the results and reference details, order at left...
5.	Neoplasm Metastasis (Metastasis) 12/01/1995 - "Docetaxel also was found to be highly effective in patients with a poor prognosis, having metastases in three or more organs (53%), and/or visceral sites of disease (47%)" 04/01/2005 - "In September 2000, she was treated with docetaxel for multiple lung metastases, and the lesions were diagnosed as in complete remission" 04/01/2004 - "A weekly administration method of docetaxel was therefore selected, resulting in complete remission of the pulmonary metastasis and a partial response of the local recurrence" 04/01/1998 - "We, therefore, treated her six times with docetaxel 80 mg, which resulted in partial response of the liver metastasis and brought about a marked decrease in serum CA15-3 levels" 09/01/1998 - "Docetaxel is not recommended for patients with liver metastases or impaired liver function because clearance of the drug is impaired" Get all the results and reference details, order at left...
256 Diseases and 3278 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	docetaxel (Taxotere)
2.	Cisplatin (Platino)
3.	gemcitabine
4.	Paclitaxel (Taxol)
5.	Hormones
6.	Carboplatin (JM8)
7.	Doxorubicin (Adriamycin)
8.	vinorelbine (Navelbine)
9.	capecitabine (Xeloda)
10.	Fluorouracil (Carac)
708 Drugs and Important Bio-Agents and 2637 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Adjuvant Chemotherapy
5.	Castration
37 Therapies and Procedures and 1151 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>